Page 2 - Perfusion Imaging News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.

A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI), according to research presented at the 2023 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. 18F-flurpiridaz PET MPI obtained images at a lower radiation dose than 99Tc-SPECT MPI and performed similarly in both obese and non-obese patients.

Giving very late thrombolysis to patients with large-vessel occlusion small core strokes did not show a significant benefit in the TIMELESS trial, although there were some encouraging findings.

321 pages of text The market for perfusion imaging is expected to grow from US$ 2.1 billion in 2022 to US$ 8.3 billion by 2032 as a result of the prevalence of neurological and cardiovascular diseases in the world.According to FMI, during the forecast period from 2022 to 2032, the perfusion imaging market is expecte...

The MR CLEAN-LATE trial shows patients selected for thrombectomy on the presence of collateral flow had a greater chance of a better functional outcome than those not receiving endovascular therapy.